According to Reuters, Esperion Therapeutics‘ ETC-1002 experimental drug has been successful in lowering LDL cholesterol levels in patients who were already taking statins. As a result of the phase-2 study, Esperion stock shares rose 19 percent and were trading at a record high of $91.50. Statins are generally considered the first-line treatment for cholesterol, but about 10 million patients taking these medications still have high cholesterol. Analysts expect this drug to be used as an additional therapy rather than an alternative therapy, or as a primary therapy for those who are statin intolerant. Current projections for the medication call for over $2 billion in sales by 2025.